DVL1 and schizophrenia: The present study has examined the effects of aripiprazole on the Akt-GSK3β and Dvl-GSK3β-β-catenin signalling pathways in three key brain regions that are related to the pathophysiology of schizophrenia, in comparison with bifeprunox and haloperidol.